TIMI Study Group

Providing the latest news and research from the TIMI Study Group, an ARO affiliated with Brigham and Women’s Hospital and Harvard Medical School.

[TIMI Study Group @TIMIStudyGroup]

TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online.
https://t.co/NXuasBCjV4

[TIMI Study Group @TIMIStudyGroup]

AF pts in 4 RCTs from COMBINE-AF show #DOACs had a favorable net clinical benefit over warfarin using a patient-weighted composite clinical outcome. Out now in @NEJMEvidence @rgiugliano
https://t.co/mQoFdxBGkR

[TIMI Study Group @TIMIStudyGroup]

Coverage in @AMJ_Reviews of @BrianBergmark's #EuroPCR presentation on PCI vs. CABG in left main disease.
https://t.co/sOmTwVWEkf

[André Zimerman @AndreZimerman]

One of my favorite projects at TIMI.

While exploratory, our findings support the concept that lowering LDL-C through PCSK9i may prevent the formation and progression of arterial aneurysms, including AAA.

Now in @CircAHA

@PrakritiGaba @marstonMD @BrianBergmark @TIMIStudyGroup

[Sunil V. Rao @SVRaoMD]

Delighted to host Christian Ruff @TIMIStudyGroup @nyulangone for Cardioloyy Grand Rounds.

The current and future state of Factor XI inhibition for #afib

[TIMI Study Group @TIMIStudyGroup]

Coverage in @CardiologyToday of @BrianBergmark's EuroPCR #VESALIUS presentation #evolocumab @ebohula @rgiugliano
https://t.co/x11ibVpzTD

[TIMI Study Group @TIMIStudyGroup]

In #VESALIUS-CV, Lp(a) was associated with risk of major coronary events and helped identify those with larger absolute benefit from #evolocumab. LBCT presentation at @EASCongress and online now at @CircAHA @rgiugliano @EBohula

https://t.co/Q9wwsOPZ81

[TIMI Study Group @TIMIStudyGroup]

Congratulations to Senior TIMI Biostatistician Andrea Bellavia, PhD, who was awarded the Teaching Citation Award from the Harvard T.H. Chan School of Public Health for excellence as a Lecturer in Biostatistics! @HarvardChanSPH

[TIMI Study Group @TIMIStudyGroup]

Similar 10-year survival following PCI vs CABG for left main disease in combined analysis of SYNTAX, PRECOMBAT, NOBLE, and EXCEL trials. @BrianBergmark #EuroPCR

[TIMI Study Group @TIMIStudyGroup]

Coverage in @TCTMD of @BrianBergmark 's #EuroPCR presentation from VESALIUS-CV (TIMI 66) #evolocumab @EBohula @rgiugliano
https://t.co/M9UZT6rswI

[TIMI Study Group @TIMIStudyGroup]

In prior PCI subgroup of VESALIUS-CV trial, #evolocumab significantly reduced MACE, including 50% reduction in MI. Presented at #EuroPCR and out now in @CircAHA @BrianBergmark @EBohula @rgiugliano
https://t.co/xvLxfXEWVI

[Circ: Heart Failure @CircHF]

Vasoactive treatment in cardiogenic shock varies widely across CICUs, driven by patient-level factors and institutional practice patterns @TIMIStudyGroup @DrRobRoswell @ICUDocAP @TIMIStudyGroup https://t.co/JiluwN0PIv

[TIMI Study Group @TIMIStudyGroup]

TIMI Senior Investigator @DrM_ODonoghue interviewed for @TIME article on important blood tests everyone should be getting.
https://t.co/hk4uiDkOOB

[TIMI Study Group @TIMIStudyGroup]

Lp(a) in @CNBC with TIMI Senior Investigator @DrM_ODonoghue
https://t.co/9urWdVcAK8

[TIMI Study Group @TIMIStudyGroup]

Listen again to the TIMI Talks podcast episode with legendary cardiologist and TIMI Study Group founder Dr. Eugene Braunwald, where he discussed his illustrious career and the beginnings of TIMI. @ddbergMD
https://t.co/0nutLNGTwC

[TIMI Study Group @TIMIStudyGroup]

Eugene Braunwald, ‘Icon’ of Modern Cardiology, Dies at 96 https://t.co/ENJletCUeS

[TIMI Study Group @TIMIStudyGroup]

While he touched many lives, we at TIMI were truly blessed to directly work with and learn from him over treasured decades. We will deeply miss him, but take comfort in knowing that we will carry forward his legacy and continue his lifelong mission to advance cardiovascular care.

[TIMI Study Group @TIMIStudyGroup]

We are deeply saddened to have lost our founding chairman and the father of modern academic cardiology, Dr. Eugene Braunwald, who founded the TIMI Study Group in 1984, and with that vision profoundly shaped the practice of cardiovascular medicine across the world.

[TIMI Study Group @TIMIStudyGroup]

More than 40 years, 80 clinical trials, and 450,000 trial participants later, we are proud that the TIMI Study Group has impacted almost every facet of cardiovascular care. Dr. Braunwald’s intellectual rigor and zeal for discovery were legendary.

[TIMI Study Group @TIMIStudyGroup]

https://t.co/El8ajy5xyL

[TIMI Study Group @TIMIStudyGroup]

Simulation from large US cohort of ACS pts shows triple lipid Rx (↑-intensity statin, ezetimibe, PCSK9i) before discharge would achieve LDL <55 mg/dL in 99.8% & <40 mg/dL in 98.7% of pts, w/a 36% further ↓ in CV events @ 5 yrs c/w ↑-intensity statin monotherapy @rgiugliano